Day: August 19, 2025

Belhaven Biopharma Closes Oversubscribed Series a to Fund the Development of Nasdepi(R) Program Moves Into Late Stage Clinical and Manufacturing Through NDA Approval

Accelerated Round Completion Positions Company for New Drug Application (NDA) Submission and Commercial Launch Partnerships RALEIGH, NORTH CAROLINA / ACCESS...

error: Content is protected !!